White blood cell inactivation after treatment with riboflavin and ultraviolet light

被引:69
作者
Marschner, Susanne
Fast, Loren A.
Baldwin, William M., III
Slichter, Sherrill J.
Goodrich, Raymond P. [1 ]
机构
[1] CaridianBCT Biotechnol LLC, Lakewood, CO 80215 USA
基金
美国国家卫生研究院;
关键词
PATHOGEN REDUCTION TECHNOLOGY; VERSUS-HOST-DISEASE; B IRRADIATION; TRANSFUSION REACTIONS; PLATELET TRANSFUSIONS; PLASMA; PRODUCTS; LEUKOREDUCTION; QUALITY; FEBRILE;
D O I
10.1111/j.1537-2995.2010.02714.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Functional white blood cells (WBCs) in blood components may be responsible for a number of adverse transfusion effects, including transfusion-associated graft-versus-host disease (TA-GVHD), alloimmunization, and alloimmune platelet (PLT) refractoriness. TA-GVHD occurs when functional lymphocytes are transfused into a patient who is unable to mount an immune response to the human leukocyte antigen (HLA) due to HLA compatibility or immunosuppression Alloantibodies against HLA antigens on donor WBCs and PLTs are the major. cause of refractoriness to PLT transfusions in patients receiving repeated blood transfusions. Attempts to reduce these undesirable effects have included leukoreduction filters and gamma irradiation Studies have shown that exposure of PLT concentrates to riboflavin and light (Mirasol pathogen reduction technology [PRT], CaridianBCT Biotechnologies) causes irreparable modifications of nucleic acids that result in inactivation of a wide range of pathogens as well as inhibition of the immunologic responses mediated by WBCs present in PLT concentrates. This article summarizes these studies and also reports on additional findings from the Trial to Reduce Alloimmunization to Platelets (TRAP) and Mirasol Clinical Evaluation (MIRACLE) trials. Data from in vitro studies and this clinical trial suggest that PRT treatment may be as effective as gamma irradiation in preventing TA-GVHD and more effective than leukoreduction in preventing alloimmunization.
引用
收藏
页码:2489 / 2498
页数:10
相关论文
共 46 条
  • [41] Serious hazards of transfusion: A decade of hemovigilance in the UK
    Stainsby, Dorothy
    Jones, Hilary
    Asher, Deborah
    Atterbury, Claire
    Boncinelli, Aysha
    Brant, Lisa
    Chapman, Catherine E.
    Davison, Katy
    Gerrard, Rebecca
    Gray, Alexandra
    Knowles, Susan
    Love, Elizabeth M.
    Milkins, Clare
    McClelland, D. Brian L.
    Norfolk, Derek R.
    Soldan, Kate
    Taylor, Clare
    Revill, John
    Williamson, Lorna M.
    Cohen, Hannah
    [J]. TRANSFUSION MEDICINE REVIEWS, 2006, 20 (04) : 273 - 282
  • [42] TASWELL C, 1981, J IMMUNOL, V126, P1614
  • [43] Trial to Reduce Alloimmunization to Platelets Study Group, 1997, N ENGL J MED, V337, P1861
  • [44] Transfusion-associated microchimerism
    Utter, G. H.
    Reed, W. F.
    Lee, T.-H.
    Busch, M. P.
    [J]. VOX SANGUINIS, 2007, 93 (03) : 188 - 195
  • [45] A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice
    van Rijn, RS
    Simonetti, ER
    Hagenbeek, A
    Hogenes, MCH
    de Weger, RA
    Canninga-van Dijk, MR
    Weijer, K
    Spits, H
    Storm, G
    van Bloois, L
    Rijkers, G
    Martens, ACM
    Ebeling, SB
    [J]. BLOOD, 2003, 102 (07) : 2522 - 2531
  • [46] The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC
    Yazer, MH
    Podlosky, L
    Clarke, G
    Nahirniak, SM
    [J]. TRANSFUSION, 2004, 44 (01) : 10 - 15